RT Journal Article
SR Electronic
T1 Epidemic waves of COVID-19 in Scotland: a genomic perspective on the impact of the introduction and relaxation of lockdown on SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.08.20248677
DO 10.1101/2021.01.08.20248677
A1 Lycett, Samantha J
A1 Hughes, Joseph
A1 McHugh, Martin P
A1 da Silva Filipe, Ana
A1 Dewar, Rebecca
A1 Lu, Lu
A1 Doherty, Thomas
A1 Shepherd, Amy
A1 Inward, Rhys
A1 Rossi, Gianluigi
A1 Balaz, Daniel
A1 Kao, Rowland R
A1 Rooke, Stefan
A1 Cotton, Seb
A1 Gallagher, Michael D
A1 Lopez, Carlos Balcazar
A1 O’Toole, Áine
A1 Scher, Emily
A1 Hill, Verity
A1 McCrone, John T
A1 Colquhoun, Rachel M
A1 Jackson, Ben
A1 Williams, Thomas C
A1 Williamson, Kathleen A
A1 Johnson, Natasha
A1 Smollett, Katherine
A1 Mair, Daniel
A1 Carmichael, Stephen
A1 Tong, Lily
A1 Nichols, Jenna
A1 Brunker, Kirstyn
A1 Shepherd, James G
A1 Li, Kathy
A1 Aranday-Cortes, Elihu
A1 Parr, Yasmin A
A1 Broos, Alice
A1 Nomikou, Kyriaki
A1 McDonald, Sarah E
A1 Niebel, Marc
A1 Asamaphan, Patawee
A1 Starinskij, Igor
A1 Jesudason, Natasha
A1 Shah, Rajiv
A1 Sreenu, Vattipally B
A1 Stanton, Tom
A1 Shaaban, Sharif
A1 MacLean, Alasdair
A1 ,
A1 Woolhouse, Mark
A1 Gunson, Rory
A1 Templeton, Kate
A1 Thomson, Emma C
A1 Rambaut, Andrew
A1 Holden, Matthew T.G.
A1 Robertson, David L
YR 2021
UL http://medrxiv.org/content/early/2021/01/20/2021.01.08.20248677.abstract
AB The second SARS virus, SARS-CoV-2, emerged in December 2019, and within a month was globally distributed. It was first introduced into Scotland in February 2020 associated with returning travellers and visitors. By March it was circulating in communities across the UK, and to control COVID-19 cases, and prevent overwhelming of the National Health Service (NHS), a ‘lockdown’ was introduced on 23rd March 2020 with a restriction of people’s movements. To augment the public health efforts a large-scale genome epidemiology effort (as part of the COVID-19 Genomics UK (COG-UK) consortium) resulted in the sequencing of over 5000 SARS-CoV-2 genomes by 18th August 2020 from Scottish cases, about a quarter of the estimated number of cases at that time. Here we quantify the geographical origins of the first wave introductions into Scotland from abroad and other UK regions, the spread of these SARS-CoV-2 lineages to different regions within Scotland (defined at the level of NHS Health Board) and the effect of lockdown on virus ‘success’. We estimate that approximately 300 introductions seeded lineages in Scotland, with around 25% of these lineages composed of more than five viruses, but by June circulating lineages were reduced to low levels, in line with low numbers of recorded positive cases. Lockdown was, thus, associated with a dramatic reduction in infection numbers and the extinguishing of most virus lineages. Unfortunately since the summer cases have been rising in Scotland in a second wave, with >1000 people testing positive on a daily basis, and hospitalisation of COVID-19 cases on the rise again. Examining the available Scottish genome data from the second wave, and comparing it to the first wave, we find that while some UK lineages have persisted through the summer, the majority of lineages responsible for the second wave are new introductions from outside of Scotland and many from outside of the UK. This indicates that, while lockdown in Scotland is directly linked with the first wave case numbers being brought under control, travel-associated imports (mostly from Europe or other parts of the UK) following the easing of lockdown are responsible for seeding the current epidemic population. This demonstrates that the impact of stringent public health measures can be compromised if following this, movements from regions of high to low prevalence are not minimised.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding for this work was received from: MRC (MC UU 1201412), Wellcome Trust Collaborator Award (206298/Z/17/Z - ARTIC Network), TCW Wellcome Trust Award 204802/Z/16/Z, Chief Scientist Office Project (COV/EDI/20/11), MRC EAVE II (MR/R008345/1), UKRI Industrial Strategy Challenge Fund BREATHE (MC_PC_19004), Scottish Government DG Health and Social Care, and Tommy's Charity (1060508, SC03928). COG-UK is supported by funding from the Medical Research Council (MRC) part of UK Research & Innovation (UKRI), the National Institute of Health Research (NIHR) and Genome Research Limited, operating as the Wellcome Sanger Institute. CLIMB is funded by the Medical Research Council (MRC) through grant MR/L015080/1. SL additionally received support from Scottish Government Rural and Environment Science and Analytical Services Division as part of Centre of Expertise on Animal Disease Outbreaks (EPIC), and the BBSRC Institute Strategic Programme grant to Roslin Institute (BB/J004235/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NHS Greater Glasgow & Clyde and Lothian biorepositories gave approval for this study under 16/WS/0207NHS and 10/S1402/33 respectively. Approval from NHS Greater Glasgow & Clyde Biorepository, NHSGGC Biorepository, Level 3, Laboratory Medicine Building, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow G51 4TY was given for this study (16/WS/0207NHS). Approval from the East of Scotland Research Ethics Service, Tayside Committee on Medical Ethics B, Research Ethics Office, TAHSC, Residency Block C Ninewells Hospital & Medical School, Dundee, DD1 9SY was given for the South East Scotland SAHSC Human Annotated BioResource and its use in relation to NHS Lothian and other NHS research (10/S1402/33).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesWe thank the Scottish NHS virology laboratories who provided samples for sequencing, the authors who have shared genome data on GISAID, https://www.gisaid.org. Our genome sequence acknowledgments can be found in the Supplementary. Online results of the analyses are displayed in http://sars2.cvr.gla.ac.uk/RiseFallScotCOVID/ (data to 2020-08-18) and http://phylodynamics.lycett.roslin.ed.ac.uk:3838/RiseFallScotCOVID/ (data to 2020-10-21) This study focuses on public health/surveillance questions in Scotland that make use of sequence data and other metadata that was collected under the activities of the COG-UK consortium (https://www.cogconsortium.uk/). COG-UK data is released and is publicly available via the ENA, GISAID and the COG-UK website. http://sars2.cvr.gla.ac.uk/RiseFallScotCOVID/ http://phylodynamics.lycett.roslin.ed.ac.uk:3838/RiseFallScotCOVID/